Development of a Clinical-Biological Model to Assess Tumor Progression in Metastatic Pancreatic Cancer: Post Hoc Analysis of the PRODIGE4/ACCORD11 Trial.

Date publication

octobre 2022

Journal

Cancers

Auteurs

Membres identifiés du Cancéropôle Est :
Pr AYAV Ahmet , Pr CONROY Thierry , Pr HARLE Alexandre , Dr LAMBERT Aurélien

Tous les auteurs :
Egea J, Salleron J, Gourgou S, Ayav A, Laurent V, Juzyna B, Harlé A, Conroy T, Lambert A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36291851

Résumé

The follow-up of pancreatic cancer (PC) is based on computed tomography (CT) assessment; however, there is no consensus on the use of clinical and biological criteria in tumor progression. We aimed to establish a clinical-biological model to highlight the progression of metastatic PC during first-line treatment.

Mots clés

CA 19-9, pancreatic cancer, patient-reported outcomes, quality of life, tumor progression

Référence

Cancers (Basel). 2022 10 16;14(20):